Skip to main content
Clinical Trials/EUCTR2011-003087-70-LV
EUCTR2011-003087-70-LV
Active, not recruiting
Not Applicable

Randomized, open-label, controlled study on the efficacy of Ciclopoli® (ciclopirox 8% nail lacquer) versus Loceryl® (amorolfine 5% nail lacquer) on the culture conversion to negative in patients with onychomycosis.

Polichem SA0 sites120 target enrollmentOctober 11, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
distal subungual onychomycosis without lunula involvement due to fungal nail pathogens (dermatophytes, white yeasts and/or Scopulariopsis spp. and/or Fusarium spp.) affecting at least one big toenail
Sponsor
Polichem SA
Enrollment
120
Status
Active, not recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 11, 2011
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Polichem SA

Eligibility Criteria

Inclusion Criteria

  • Written informed consent before starting any study related procedures
  • Patients aged 18 up to 75 years old
  • Males or females
  • Patients with established clinical diagnosis of distal sub\-ungual onychomycosis caused by fungal nail pathogens, affecting at least one big toenail with indication for topical treatment
  • Patients with both positive KOH and culture for fungal nail pathogens (dermatophytes, white yeasts and/or Scopulariopsis spp. and/or Fusarium spp.) in screening target nail sample.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 90
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Patients with Yellow spikes on the target nail (extension of fungal infection from distal to proximal part of nail)
  • Patients with lunula involvement (marker of immunosuppressed patient)
  • Patients with negative KOH examination at screening
  • Patients with proximal subungual involvement (marker of immunosuppressed patient)
  • Patients with severe plantar or moccasin tinea pedis (defined by blistering, pustules or inability to ambulate)
  • Patients with nail abnormalities due to conditions like psoriasis or lichen planus
  • Patients using nail polish or other nail cosmetic product on the concerned nails from at least 24 hours prior to study drug administration until the end of the study.
  • Patients with target nail hyperkeratosis exceeding 4 mm in thickness
  • Use of any topical antifungal drugs (including investigational drug) or participation in an investigational study within 30 days prior to administration of study medication

Outcomes

Primary Outcomes

Not specified

Similar Trials